EPI Health, a Novan Company, and MC2 Therapeutics present Wynzora cream, 0.005%/0.064% subgroup data analysis at Skin of Color Update 2022 Conference.

Published as a poster, this analysis from a previously completed Phase III randomized, multicenter, investigator-blind, parallel-group trial of Wynzora Cream (calcipotriene and betamethasone dipropionate) evaluated efficacy and convenience factors in skin of color patients compared to the total study.

Patients with skin of color are typically not well represented in topical psoriasis studies. This data enables us to understand the efficacy of Wynzora Cream in this population, which comprised more than one third of patients enrolled. The results from this analysis demonstrated similar efficacy and comparable or higher scores for convenience factors (such as how easy the treatment was to apply) in Fitzpatrick skin type IV to VI subjects, giving us further confidence in using Wynzora for these patients,” commented Fran Cook-Bolden M.D., Assistant Clinical Professor, Weill Cornell Medicine New York, NY and an investigator for the WYNZORA Cream US Phase III study.

Title: "Calcipotriene (CAL) and betamethasone dipropionate (BDP) cream demonstrates high efficacy and convenience in skin of color patients with plaque psoriasis": Authors: Valerie Callender, MD, Susan Taylor, MD and Fran Cook-Bolden, MD Stein Gold et al, J Drugs Dermatol 2021;20(4).